Please login to the form below

Not currently logged in
Email:
Password:

BIO

This page shows the latest BIO news and features for those working in and with pharma, biotech and healthcare.

BMS and bluebird bio gain FDA approval for multiple myeloma therapy

BMS and bluebird bio gain FDA approval for multiple myeloma therapy

The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb (BMS) and bluebird bio’s BCMA-targeting CAR T cell therapy Abecma – previously known as ide-cel – for the ... Samit Hirawat, chief medical officer, BMS said: “CAR T cell

Latest news

More from news
Approximately 44 fully matching, plus 213 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 36 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • A day in the life of the Global Head of Publications A day in the life of the Global Head of Publications

    I built publications departments at several mid-sized bio-pharmaceutical companies before returning to a medical communications agency last year when I joined OPEN Health.

  • EPG Health EPG Health

    Strategic planning - to ensure ongoing engagement and success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, GSK, HRA Pharma, Janssen, Leo Pharma, Lilly,

  • HARNESSING TECHNOLOGY TO TRANSFORM HEALTHCARE IN THE DIGITAL AGE

    3D-printed, bio-engineered heart in April 2019, to where we are now - a bionic hybrid heart developed in January this year. ... Engineered hearts: Mentioned above, 3D printed bio-engineered hearts created from a patient’s own cells remove the need for

  • Putting people and the planet first in 2020

    At this years’ ISPOR and BIO-Europe conferences we took the decision that our exhibition stand was to be made using as many recycled and reusable components as possible and would

  • Generating data on long-term outcomes with gene and other advanced therapies

    Long-term monitoring of patients to collect outcome data after treatment with these therapies will be standard practice for the foreseeable future; it will therefore be necessary for bio-pharma and ... Bio-pharma are required to adhere to strict

More from PMHub
Approximately 4 fully matching, plus 32 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics